"Its GSK Buyout of ACL is Not Possible
Anti competitive Laws would not allow it"
mmmm, I'm not so sure of that. Aritra has plenty of competition from Lovenox and its generics. Also, acl are no competition to gsk at the moment, as they cannot sell their product (yet).
A long time ago Bioshares suggested that gsk would be interested in acl's manufacturing process, which is quicker and cheaper. They would also get their hands on all the HyACT stuff.
It would actually make sense for gsk to buy out acl to retain their market share. I'm not so sure it will happen though.
"Its GSK Buyout of ACL is Not PossibleAnti competitive Laws...
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable